FibroGen (NASDAQ:FGEN) CEO Thomas B. Neff sold 39,636 shares of the firm’s stock in a transaction that occurred on Wednesday, April 18th. The stock was sold at an average price of $48.56, for a total transaction of $1,924,724.16. Following the transaction, the chief executive officer now owns 2,933,653 shares in the company, valued at $142,458,189.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ FGEN opened at $46.40 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.70 and a quick ratio of 9.70. FibroGen has a 1-year low of $25.35 and a 1-year high of $63.00. The firm has a market cap of $3,980.42, a P/E ratio of -26.82 and a beta of 1.89.
FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.01. FibroGen had a negative return on equity of 32.08% and a negative net margin of 100.43%. The firm had revenue of $42.51 million during the quarter, compared to the consensus estimate of $45.37 million. sell-side analysts predict that FibroGen will post -1.35 earnings per share for the current fiscal year.
A number of equities analysts have recently issued reports on the stock. ValuEngine lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st. Zacks Investment Research lowered shares of FibroGen from a “hold” rating to a “sell” rating in a research report on Monday, March 5th. Mizuho restated a “hold” rating and set a $61.00 target price on shares of FibroGen in a research report on Thursday, March 29th. Leerink Swann restated an “outperform” rating and set a $88.00 target price (up from $80.00) on shares of FibroGen in a research report on Wednesday, February 28th. Finally, TheStreet upgraded shares of FibroGen from a “d” rating to a “c-” rating in a research report on Tuesday, February 27th. Two analysts have rated the stock with a sell rating, three have given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $66.67.
ILLEGAL ACTIVITY WARNING: “Thomas B. Neff Sells 39,636 Shares of FibroGen (FGEN) Stock” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://stocknewstimes.com/2018/04/21/thomas-b-neff-sells-39636-shares-of-fibrogen-fgen-stock-2.html.
FibroGen Company Profile
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.